Core Viewpoint - The article discusses the recent success of the Global Vaccine Alliance (Gavi) in securing over $9 billion in funding for the next five years, despite a significant shortfall from its $11.9 billion target, highlighting the critical role of vaccination in public health and the challenges posed by declining global health financing [1][5]. Group 1: Funding and Contributions - Gavi has raised over $9 billion for the period from 2026 to 2030, with the UK leading contributions at £1.25 billion (approximately ¥122.3 billion) and the Gates Foundation contributing $1.6 billion (approximately ¥114.7 billion) [5]. - The European Commission and member states collectively contributed over €2 billion (approximately ¥168.8 billion) [5]. - The withdrawal of U.S. funding, which previously contributed around $300 million annually, poses a significant challenge to Gavi's operations [5][6]. Group 2: Gavi's Operational Model - Gavi operates on a co-financing model where even low-income countries contribute $0.2 per vaccine dose, gradually increasing their financial responsibility as their economies grow [7]. - This model has allowed 19 countries to achieve self-sufficiency in vaccine funding [7]. Group 3: China's Role and Collaboration - China has transitioned from a Gavi recipient to a donor, contributing over $120 million since 2016, and is seen as a model for Gavi's empowerment strategy [9]. - The collaboration began in 2002 with a hepatitis B vaccination program, significantly increasing vaccination rates in impoverished regions [9]. Group 4: Vaccine Development and Global Health - Gavi has facilitated the entry of Chinese vaccines into international markets, with over 540 million doses of the encephalitis vaccine exported to low- and middle-income countries [10]. - Gavi aims to establish a global vaccine reserve for diseases like monkeypox, emphasizing the need for innovative delivery methods in low-resource settings [11][12]. Group 5: Leadership and Vision - Sania Nishtar, the first CEO from a developing country, emphasizes the importance of health equity and the urgent need for global vaccination efforts, especially as millions of children remain unvaccinated [14][15].

Core Points - The Global Vaccine Alliance (Gavi) successfully raised over $9 billion for the next five years (2026-2030) during the "Immunization for Health and Prosperity" summit in Brussels, despite a significant decline in global health financing [1][3] - Gavi has provided vaccines to over 1 billion children since its inception in 2000, preventing more than 18 million avoidable deaths, and currently serves nearly half of the world's children [1][3] - The UK and the Bill & Melinda Gates Foundation are the largest contributors, with the UK pledging £1.25 billion (approximately $1.6 billion) and the Gates Foundation contributing $1.6 billion [3] - The U.S. has historically been a significant donor, contributing around $300 million annually, but announced it would stop funding Gavi, which could impact global vaccination efforts [3][4] Funding and Contributions - The total commitments for the next five years include £1.25 billion from the UK, $1.6 billion from the Gates Foundation, and over €360 million from the European Commission and member states, totaling over €2 billion [3] - Indonesia, which recently graduated from Gavi's support list, pledged $30 million for the next five years, showcasing a shift from recipient to donor [5] Gavi's Operational Model - Gavi operates on a co-financing model where even low-income countries contribute a small amount per vaccine dose, gradually increasing their financial responsibility as their economies grow [5] - Gavi's CEO, Sania Nishtar, emphasized the importance of maintaining communication with the U.S. government to secure ongoing support [5] China's Role - China is highlighted as a successful example of Gavi's empowerment model, transitioning from a recipient to a donor, contributing over $120 million since 2016 [7] - The collaboration between China and Gavi began in 2002 with a hepatitis B vaccination program, significantly increasing vaccination rates in impoverished regions [7][8] Vaccine Development and Innovation - Gavi is focusing on expanding its vaccine portfolio, including support for vaccines against hepatitis E, tuberculosis, and monkeypox, as part of its 6.0 vaccine investment strategy [8][9] - Gavi is interested in innovative delivery methods, such as microneedle patches, to improve vaccine accessibility in low-resource settings [9][10] Leadership and Vision - Sania Nishtar, the first CEO from a developing country, brings a unique perspective to Gavi, having witnessed the impact of vaccine-preventable diseases firsthand [12][13] - Nishtar's background as a physician and public health advocate informs her commitment to ensuring health and immunization as fundamental human rights [13]